Project 1 - Endogenous and Exogenous Mechanisms that Promote Myocardial Remuscularization

项目 1 - 促进心肌再肌化的内源性和外源性机制

基本信息

批准号：
10493838
负责人：
Jianyi Zhang
金额：
$ 39.8万
依托单位：
UNIVERSITY OF ALABAMA AT BIRMINGHAM
依托单位国家：
美国
项目类别：
财政年份：
2022
资助国家：
美国
起止时间：
2022-09-01 至 2027-08-31
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10493838
关键词：
3-Dimensional Acute myocardial infarction Adult Animals Apoptotic Arrhythmia Back Biomedical Engineering Birth Blood Vessels CCND2 gene Cardiac Cardiac Myocytes Cell Cycle Cell Line Cell Nucleus Cell Transplantation Cells Cicatrix Congestive Heart Failure Cues Dilatation - action Dimensions Electric Stimulation Endogenous Factors Endothelium Engineering Engraftment Family suidae Fibroblasts Functional disorder Generations Heart Heart failure Human Human Engineering Imaging technology Injury Left Left Ventricular Remodeling Left ventricular structure Mammals Measurement Molecular Molecular Biology Mus Muscle Cells Myocardial Myocardial tissue Myocardium Natural regeneration Neonatal Optics Patients Periodicity Pilot Projects Proliferating Protocols documentation Public Health RNA Recovery Regimen Regulatory Pathway Reporting Rodent Model Signal Pathway Site Smooth Muscle Stretching Surface Techniques Technology Testing Therapeutic Thick Tissue Engineering Tissues Transplantation Vascularization Ventricular Ventricular Arrhythmia base cardiac tissue engineering cell type clinically relevant effectiveness evaluation endothelial stem cell functional improvement heart function improved in vivo induced pluripotent stem cell injured ischemic injury mature animal molecular imaging myocardial injury novel overexpression porcine model postnatal prevent promoter regeneration potential repaired restoration success transcriptome sequencing

项目摘要

SUMMARY / ABSTRACT (Project 1) Endogenous and Exogenous Mechanisms that Promote Myocardial Remuscularization in Postinfarction LV Remodeling The molecular and cellular basis for progressive heart failure is the result of the inability of damaged and apoptotic myocytes to be replaced. While a number of cell- and tissue-based therapies can limit this dysfunction, the proportion of cells that survive at the site of administration for more than a few weeks after transplantation is extremely low. As such, substantial remuscularization of the infarcted region has rarely been reported; and when limited remuscularization has been reported, it is frequently accompanied by potentially lethal ventricular arrhythmias of unknown mechanism. This proposal aims at remuscularization of the injured ventricle by the definition of key endogenous factors that regulate and promote the cell cycle of the native cardiomyocyte (CM), and from exogenous transplanted bioengineered cardiac muscle patch (hCMP) that overexpresses key regulators of CM cell cycle, and will incorporate a functional vascular network and recapitulate some of the key micro environmental cues of native heart tissue. We recently established a novel hiPSC cell line with MHC-driven overexpression of a key regulator of CMs: CCND2 (hiPSC-MHC-CCND2OE), which can remuscularize injured ventricle in rodent model. The central objective of this proposal is to “turn back the clock” of the myocyte cell cycle, which will facilitate myocardial repair. The Specific Aims (SA) that will examine this objective include: SA1: To identify the key regulators that promote cell-cycle activity in the hearts of early neonatal pigs after myocardial injury. We will: 1) using state-of-the-art fate-mapping molecular biology and imaging technologies, and the single cell/nucleus RNA sequencing (scRNAseq or snRNAseq) technology demonstrate the key regulators/signaling pathways that govern the myocyte cell cycle; and 2) test the remuscularization of the injured ventricle by manipulating the key regulators using either targeted modRNA or AAV9 delivery strategies to selectively modify these regulators in adult pig hearts following ischemic injury. SA2a. To engineer hCMPs containing CMs that are capable of proliferating after transplantation, and characterized by previously unattainable size and thickness that are functionally mature and primed for in-vivo vascularization. SA2b. To evaluate the effectiveness of our hCMP constructs for myocardial recovery and remuscularization in a large-animal (pig) model of myocardial injury. We will use state-of-the-art techniques that includes optical mapping in combination with the 3- dimensional intramural cardiac mapping to delineate the potential arrhythmia mechanisms over the entire transmural and left ventricular surface. These studies will synergize with the other projects and serve as a prelude for therapeutic initiatives focused on remuscularization of the injured human heart.

摘要/摘要（项目1）促进的内源性和外源性机制梗塞后左室重构中的心肌再肌化进行性心力衰竭的分子和细胞基础是受损和无力的结果。虽然许多基于细胞和组织的疗法可以限制这种功能障碍，移植后在给药部位存活数周以上的细胞比例为因此，很少有梗塞区域的大量再肌化的报道；据报道，有限的再肌化，经常伴随着潜在致命的心室机制不明的心律失常该提案旨在通过损伤的心室进行肌力重建。调节和促进天然心肌细胞（CM）细胞周期的关键内源因子的定义，以及来自外源移植的生物工程心肌补片（hCMP），其过度表达关键 CM 细胞周期的调节因子，并将整合功能性血管网络并概括一些关键我们最近建立了一种由 MHC 驱动的新型 hiPSC 细胞系。 CM 关键调节因子的过度表达：CCND2 (hiPSC-MHC-CCND2OE)，可以使受伤的肌肉重新恢复该提案的中心目标是“让时钟倒转”啮齿动物模型中的心室。周期，这将促进心肌修复将检查此目标的具体目标 (SA) 包括： SA1：确定促进早期新生猪心肌细胞周期活动的关键调节因子我们将：1）使用最先进的命运图谱分子生物学和成像技术，以及单一的方法。细胞/细胞核 RNA 测序（scRNAseq 或 snRNAseq）技术展示关键调控因子/信号传导控制心肌细胞周期的途径；2) 通过以下方式测试受损心室的肌重化：使用靶向 modRNA 或 AAV9 递送策略来选择性地修改关键调节因子这些调节剂在成年猪心脏缺血损伤后被改造为含有 CM 的 hCMP。移植后能够增殖，其尺寸和厚度是以前无法达到的功能成熟并已准备好进行体内血管化以评估我们的 SA2b 的有效性。 hCMP 构建体用于大型动物（猪）心肌模型中的心肌恢复和再肌化我们将使用最先进的技术，包括光学测绘与 3- 相结合。三维壁内心脏测绘，描绘整个过程中潜在的心律失常机制这些研究将与其他项目协同作用并作为前奏。表彰专注于受伤心脏肌肉重建的治疗举措。